ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Efficacy and safety of anlotinib plus XELOX regimen as first-line therapy for mCRC: a single-arm, multicenter, phase II study (ALTER-C-001)

Song, Bo; Hu, Hai; Zhang, Li; Ye, Su-Juan; Jin, Yong-Dong; Shang, Chang-Ling; Zhang, Jun; Sun, Hao; Zhang, Ke; Yi, Bo; Han, Yun-Wei*; Yan, Jin*电子科技大学; 重庆大学
Frontiers in Oncology2023-9-1DOI: 10.3389/fonc.2023.1238553
5阅读
引用收藏
分享

摘要

BackgroundAnlotinib showed encouraging anti-tumor activity in metastatic colorectal cancer (mCRC). This study was designed to assess the efficacy and safety of anlotinib plus XELOX as first-line therapy in mCRC patients.Materials and MethodsEligible patients aged & GE;18 with mCRC were enrolled in this multicenter, single-arm, phase II, exploratory study. Patients received at least 6 cycles of anlotinib, oxaliplatin, and capecitabine as initial therapy. Subsequently, patients received anlotinib monotherapy as maintenance therapy until tumor progression or intolerable toxicity. The primary endpoint was progression-free survival (PFS).ResultsThirty-one patients were included between December 2019 and March 2022. The median follow-up was 17.5 (95% CI, 3.0-17.5) months. The median PFS was 8.3 (95% CI, 6.3-10.0) months, with 6- and 12-month PFS rates of 82.3% (95% CI, 59.2%-93.0%) and 18.9% (95% CI, 4.8%-40.1%), respectively. Fifteen (48.4%) achieved partial response for an ORR of 48.4% (95% CI, 30.2%-66.9%). The disease control rate was 71.0% (95% CI, 52.0%-85.8%) due to 7 (22.6%) stable diseases. The median duration of response was 6.0 (95% CI, 3.6-8.0) months and 1 patient had the longest ongoing response of 17.3 months. Of 24 patients with evaluable imaging, 23 (74.2%) obtained tumor shrinkage. The median PFS (11.0 vs. 6.9 months) and ORR (66.7% vs. 60.0%) for patients with RAS/BRAF wild-type were numerically better than those with mutation. Three patients are still ongoing treatment. The grade 3 or more treatment-emergent adverse events (TEAEs) were mainly hypertension (12.9%) and decreased neutrophil count (12.9%). Four (12.9%) had serious TEAEs, primarily including abdominal pain and incomplete intestinal obstruction.ConclusionAnlotinib plus XELOX as first-line therapy in patients with mCRC showed anti-tumor activity and safety profile, which is worth further investigation.Clinical Trial Registrationchictr.org.cn, identifier ChiCTR1900028417.

学科与关键词

关键词
anlotinibXELOXmetastatic colorectal cancerefficacysafetyfirst-line therapy
相关
加载中…
  • A Randomized Phase III Study of Anlotinib Versus Bevacizumab in Combination With CAPEOX as First-Line Therapy for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Clinical Trial Protocol
    He, Jinjie; Liu, Yue; Liu, Chengcheng; Hu, Hanguang; Sun, Lifeng; Xu, Dong; Li, Jun; Wang, Junye; Chen, Xiaobing; Lin, Rongbo; Jiang, Yi; Zhang, Yanqiao; Zhang, Weisheng; Cheng, Ying; Wu, Xiaohong; Fang, Mingzhi; Li, Enxiao; Xu, Ye; Chen, Ye; Li, Jiayi; Cui, Yanyan; Pan, Zhanyu; Zhang, Songnan; Yuan, Ying; Ding, Kefeng*TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2023, 22: 15330338231152350.被引 2
  • Updated results from ALTER-C001 study: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC.
    Yan, Jin; Han, Yunwei; Zhang, Li; Jin, Yongdong; Sun, HaoGenitourinary Cancers Symposium, San Francisco, CA, 2023-01-19 To 2023-01-21.
  • Update of a phase II, multicenter clinical trial: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC.
    Yan, Jin; Han, Yunwei; Zhang, Li; Jin, Yongdong; Sun, HaoAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Oncology
发表日期
2023-09-01
卷期
第 13 卷
页码
1238553
DOI
10.3389/fonc.2023.1238553
成果收录
SCIE

作者

  • S

    Song, Bo (第一作者)

    sichuan canc hosp & inst · univ elect sci & technol china

  • H

    Hu, Hai

    sichuan canc hosp & inst · univ elect sci & technol china

查看全部 12 位作者收起作者
  • Z

    Zhang, Li

    univ three gorges

  • Y

    Ye, Su-Juan

  • J

    Jin, Yong-Dong

    sichuan canc hosp & inst · univ elect sci & technol china

  • S

    Shang, Chang-Ling

  • Z

    Zhang, Jun

    univ three gorges

  • S

    Sun, Hao

    chongqing univ

  • Z

    Zhang, Ke

    sichuan canc hosp & inst · univ elect sci & technol china

  • Y

    Yi, Bo

    sichuan canc hosp & inst · univ elect sci & technol china

  • H

    Han, Yun-Wei (通讯)

  • Y

    Yan, Jin (通讯)

    sichuan canc hosp & inst · univ elect sci & technol china

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417